Subclinical myocarditis remains the blind spot in immune therapy cardiotoxicity
A BMJ rapid response on cardiovascular toxicity from cancer immunotherapy draws attention to a problem that sits just below the surface of routine oncology practice: subclinical immune-checkpoint-inhibitor-associated myocarditis, often detected only through an isolated troponin rise. Symptomatic myocarditis is dramatic and unmistakable, but the quieter form creates a harder clinical dilemma because the patient may feel well while laboratory evidence hints at myocardial injury.
The concern is not academic. Troponin elevation without chest pain, dyspnea, arrhythmia, or heart failure symptoms may represent early inflammatory injury that could later evolve into overt myocarditis. It may also reflect a false alarm, a laboratory abnormality with little immediate clinical meaning. Those two possibilities lead to very different bedside decisions, yet current practice does not reliably separate them.
Troponin screening can prevent missed injury, or trigger avoidable treatment changes
The case for routine biomarker surveillance is straightforward on paper. Serial troponin testing during immune checkpoint inhibitor therapy could identify patients before they deteriorate, when immunosuppression and treatment interruption might avert a catastrophic myocarditis presentation. In a disease where progression can be rapid, earlier detection has obvious appeal.
The counterargument is equally strong. Repeated troponin checks can generate false positives, especially in oncology patients who often carry multiple competing reasons for biomarker fluctuation. A single abnormal result may lead to unnecessary interruption of immune checkpoint inhibitor therapy, additional cardiac testing, specialist referrals, and patient anxiety. For a treatment that may be controlling a life-threatening cancer, stopping therapy on the basis of an uncertain biomarker signal carries real consequences.
Isolated troponin elevation therefore sits in a diagnostic gray zone. One one hand it may mark indolent myocardial inflammation that deserves action; on the other it may be benign laboratory noise. The absence of consensus on universal baseline or serial cardiac biomarker screening leaves clinicians to improvise, and improvisation in cardio-oncology rarely produces consistency across centers.
Risk stratification is still too crude for routine practice
A central message in the response is that better risk stratification is needed before screening can become truly useful. Some patients are already known to be at higher risk, including those receiving combination immune checkpoint inhibitor regimens and those with thymoma. Those factors are clinically important, but they do not provide a sufficiently precise map of who needs closer surveillance and who can safely avoid intensive testing.
In practical terms, the field lacks validated predictive biomarkers that would let clinicians prospectively identify vulnerable patients before myocardial injury becomes visible. Without such tools, pre-treatment cardiac work-up varies widely and depends heavily on local culture, specialist access, and individual physician caution. The result is a patchwork of screening habits rather than a coherent standard of care.
A troponin rise in an asymptomatic patient should not be treated as a binary yes-or-no event. The biological signal may represent an early inflammatory phase in the myocardium, but the clinical meaning depends on trajectory, associated findings, and patient-specific risk. Current care pathways do not yet capture that complexity well enough to guide a uniform response.
The management gap is widest when symptoms are absent
Severe symptomatic ICIMy warrants prompt high-dose immunosuppression, and that point is not in dispute. The harder question is what to do when troponin rises in the absence of symptoms. In that setting, clinicians face an uncomfortably broad set of options: hold immunotherapy, start steroids, intensify cardiac monitoring, or watch closely without immediate intervention.
Each approach has trade-offs. Holding immunotherapy may protect the heart but risks compromising cancer control. Steroids may suppress evolving myocarditis but expose patients to immunosuppressive toxicity and could be unnecessary if the troponin elevation is not clinically meaningful. Watch-and-wait preserves cancer treatment but may allow silent myocardial inflammation to progress. The absence of outcome data for this subgroup leaves bedside decision-making vulnerable to individual preference rather than evidence.
The uncertainty is especially problematic because subclinical disease is increasingly recognized in real-world cohorts. As oncology regimens expand and immune checkpoint inhibitors move into broader use, the number of patients with mild or isolated biomarker abnormalities will only increase. A management strategy built around severe presentations alone will miss the growing population that sits between wellness and fulminant toxicity.
Real-world registries could define the natural history of silent myocardial injury
The authors call for prospective real-world registries to define how subclinical ICIMy behaves over time. That is a sensible next step because randomized trials are unlikely to answer this question cleanly. The population is heterogeneous, the event rates are probably low, and the decision to intervene is tightly linked to clinician judgment and local protocols.
A registry could help answer several practical questions at once: how often isolated troponin elevation precedes symptomatic myocarditis, which patients convert to clinically significant disease, and whether any screening pattern meaningfully changes outcomes. Just as important, it could show how frequently biomarker abnormalities never progress, a finding that would temper overreaction to every laboratory signal.
The biological appeal of serial troponin monitoring lies in inflammation detection. Immune checkpoint blockade can unleash T-cell activity against tumor tissue, but the same immune activation may spill into the myocardium and generate inflammatory injury. If caught early, that process might be interruptible. If not, it can evolve into a dangerous cardiac syndrome that is harder to reverse once symptoms appear.
Cardio-oncology needs a narrower, more workable screening algorithm
The argument made here is not for indiscriminate testing of every patient on immune therapy. It is for a risk-stratified approach that reflects the actual uncertainty at the bedside. Routine universal screening may be too blunt, but no screening at all may miss the very patients who would benefit most from early intervention.
Current guidelines vary widely on pretreatment cardiac testing, and that inconsistency filters directly into daily oncology practice. Some centers may check troponin and electrocardiography liberally, while others reserve testing for symptoms or high-risk regimens. In a field where time-sensitive decisions can determine whether myocarditis is caught early or after clinical deterioration, this variability has real consequences.
The clinical task ahead is straightforward to state and difficult to execute: distinguish meaningful myocardial inflammation from noise, identify the patients most likely to progress, and define when immunotherapy should be held. Until prospective data fill that gap, isolated troponin elevation will remain one of the least settled findings in cardio-oncology.